M&A Corner
bit.bio Enhances R&D with Ginkgo Partnership07 Mar 2024
bit.bio joins Ginkgo Bioworks’ Technology Network to enhance R&D capabilities. Their ioCells, crafted with precision reprogramming technology, integrate seamlessly into... Continue Reading
|
Veradigm Acquires ScienceIO | Empowering Healthcare Data Innovation05 Mar 2024
Veradigm announces the acquisition of ScienceIO, a healthcare data and technology provider, in a $140 million deal. Approved by Veradigm’s... Continue Reading
|
Biologics Powerhouse: BioCina and NovaCina Join Forces05 Mar 2024
BioCina Pty Ltd. and NovaCina Pty Ltd. have formed a strategic alliance to provide integrated biologics solutions. BioCina will leverage... Continue Reading
|
NGM Bio Acquired in $135M Deal by Column Group05 Mar 2024
NGM Bio, a biotech company, is being acquired by affiliates of The Column Group, LP. The agreement, with Atlas Neon... Continue Reading
|
Bristol Myers Squibb Acquires RayzeBio | Radiopharmaceutical Expansion05 Mar 2024
Bristol Myers Squibb has successfully acquired RayzeBio, Inc., adding radiopharmaceutical therapeutics to its portfolio. The acquisition, completed through a tender... Continue Reading
|
PCM Trials Boosts Diversity: Acquires EmVenio Research29 Feb 2024
PCM Trials, a Denver-based leader in decentralized clinical trials, has acquired EmVenio Research to enhance patient-centricity. This collaboration strengthens their... Continue Reading
|
Waltz Health | Redefining Medicare Drug Affordability29 Feb 2024
Discount drug company Waltz Health enters Medicare market, aiding health plans with affordable prescription access via AI-powered search engine. Initial... Continue Reading
|
GAVRETO® Acquisition | Rigel Advances Oncology Portfolio Growth29 Feb 2024
Rigel Pharmaceuticals acquires U.S. rights to GAVRETO®, a FDA-approved treatment for metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and... Continue Reading
|
Gracell Biotech | AstraZeneca Acquisition Fuels Future Innovations29 Feb 2024
Gracell Biotechnologies, a biopharmaceutical company specializing in cancer and autoimmune disease treatments, has been successfully acquired by AstraZeneca. Shareholders approved... Continue Reading
|
DarioHealth’s $10M Twill Acquisition Expands Chronic Care Portfolio29 Feb 2024
DarioHealth completes a $10 million acquisition of Twill, bolstering its digital health offerings for chronic conditions. The strategic move creates... Continue Reading
|